Is Lamotrigine Safe in Pregnancy? Birth Defect Risks

Lamotrigine is one of the safer antiseizure medications available for use during pregnancy, and current clinical guidelines from the American Academy of Neurology, American Epilepsy Society, and Society for Maternal-Fetal Medicine list it among the preferred options for women who need seizure control while pregnant.¹ That does not mean the risk is zero, though. The evidence tells a more granular story that depends on dose, what other medications are taken alongside it, and which specific outcomes you look at.

What the Overall Malformation Data Show

The baseline rate of major birth defects in the general population sits around two to three percent. When researchers track pregnancies exposed to lamotrigine monotherapy during the first trimester, the malformation rate consistently lands in that same range. The International Lamotrigine Pregnancy Registry, which followed over 1,500 first-trimester monotherapy exposures across 18 years, did not detect a meaningful increase in major congenital malformations.² A separate large observational study found that about 3.7% of infants exposed to lamotrigine had a major birth defect, a rate that was not statistically different from the background rate once adjustments were made.³

A UK comparative study reported a lamotrigine monotherapy malformation rate of about 2.7%, compared with 2.2% in women with epilepsy who took no antiseizure medication during pregnancy.⁴ The Australian Pregnancy Register reported a slightly higher figure of 4.9% for lamotrigine, compared with 3.4% in untreated women with epilepsy, but that difference was not statistically significant either.⁵ Across studies, the numbers bounce around a bit depending on the registry, the population studied, and how “major malformation” is defined, but the consistent finding is that lamotrigine monotherapy does not push the malformation rate meaningfully above what you would expect in any pregnancy.

The Oral Cleft Question

One specific concern that surfaced early in lamotrigine’s pregnancy safety record involves oral clefts, particularly isolated cleft palate. In 2008, researchers analyzing data from the North American Antiepileptic Drug Pregnancy Registry reported a roughly tenfold increase in isolated oral clefts among lamotrigine-exposed infants compared to an unexposed hospital population. Five infants out of about 680 exposures had oral clefts, a rate of 7.3 per 1,000. When they compared this to lamotrigine-exposed infants in five other registries, the rate dropped to 2.5 per 1,000, but was still about four times higher than expected.⁶

That initial finding got a lot of attention. But when larger datasets were assembled to test it, the signal weakened. A European study using data from the EUROCAT network looked at 147 lamotrigine monotherapy-exposed babies with congenital anomalies and found no statistically significant increase in oral clefts overall, in isolated oral clefts, or in isolated cleft palate specifically.⁷ A more recent analysis of birth defects linked to antiseizure medications did find an association between lamotrigine and cleft lip/palate, but valued this finding alongside the fact that valproate and carbamazepine had much broader and stronger associations with multiple types of defects.⁸

The honest summary is that the oral cleft signal has not been conclusively ruled out, but it also has not been consistently replicated in the larger studies that followed. If there is an increased risk, it appears to be small in absolute terms. This is a situation where the science has gone back and forth, and most clinicians treat it as a possible but unconfirmed association rather than a settled risk.

How Lamotrigine Compares to Other Antiseizure Medications

This is where lamotrigine’s relative safety profile really stands out. A large network meta-analysis pooling data from many studies found that lamotrigine showed no increased risk of major congenital malformations compared to untreated controls. Its odds ratio sat right at 0.96, meaning essentially no difference. By contrast, valproate carried roughly a threefold increase in risk, phenobarbital and phenytoin about a 1.7 to 1.8 times increase, and even carbamazepine showed a statistically significant 1.4 times increase. Only levetiracetam had a comparable safety profile to lamotrigine.⁹

The comparison with valproate is especially stark. The Australian register found valproate’s malformation rate at about 15%, compared with lamotrigine’s 4.9%.⁵ The UK comparative study put valproate at 6.6% versus lamotrigine’s 2.7%.⁴ Every major dataset tells the same story: valproate poses substantially higher teratogenic risk, and lamotrigine is among the lowest-risk options available.

The UK and Ireland Epilepsy and Pregnancy Registers reinforced this further, finding that even high-dose lamotrigine was associated with fewer malformations than any dose of valproate.¹⁰ This is why current practice guidelines specifically recommend lamotrigine, levetiracetam, or oxcarbazepine as preferred choices for women planning pregnancy.¹

Does Dose Matter?

For some antiseizure medications, particularly valproate, the risk of birth defects increases with higher doses. Lamotrigine does not appear to follow that pattern. The International Lamotrigine Pregnancy Registry analyzed 802 monotherapy exposures and found no relationship between first-trimester dose and the frequency of major birth defects, up to 400 mg per day. The median dose was the same (200 mg/day) for infants with and without malformations.¹¹

The Australian Pregnancy Register came to the same conclusion using a different dataset, finding no tendency for fetal risk to increase with increasing lamotrigine dose.⁵ This is reassuring because, as we will see shortly, pregnancy itself drives lamotrigine levels down, and many women need dose increases during pregnancy just to maintain seizure control. Knowing that higher doses do not appear to translate into higher malformation risk gives clinicians more room to adjust as needed.

When Other Medications Are Added

The safety picture changes substantially when lamotrigine is combined with other antiseizure medications, especially valproate. Data from the North American registry found that among infants exposed to lamotrigine plus valproate, the malformation rate was about 9%, roughly five times higher than the odds with lamotrigine alone. When lamotrigine was combined with other medications that were not valproate, the rate dropped to about 2.9%, which is close to the monotherapy rate.¹²

An earlier analysis from the International Lamotrigine Registry told a similar story: about 12.5% of pregnancies with lamotrigine plus valproate resulted in major birth defects, compared with 2.7% for lamotrigine combined with drugs other than valproate.¹³ The takeaway is clear: valproate is the main driver of risk when it appears in any combination. Avoiding it during pregnancy remains one of the most impactful decisions for reducing birth defect risk.

More recent data have also flagged the combination of lamotrigine with topiramate. Compared with lamotrigine monotherapy, the lamotrigine-topiramate combination carried a roughly 4.5-fold increase in malformation risk.¹⁴ Combinations with levetiracetam, carbamazepine, or zonisamide did not reach statistical significance for increased risk in that analysis, though the confidence intervals were wide enough that the data were not definitive. If you are taking lamotrigine alongside another antiseizure medication, this is a conversation worth having with your neurologist before or early in pregnancy.

How Pregnancy Alters Lamotrigine Levels

Lamotrigine is primarily eliminated from the body through a liver enzyme called UGT1A4. During pregnancy, rising estrogen levels upregulate this enzyme, which means the body clears lamotrigine faster than usual.¹⁵ Blood levels can drop significantly, sometimes beginning in the first trimester. In one study, lamotrigine clearance decreased significantly in the first half of the first trimester and remained lower throughout pregnancy, and about 40% of the pregnancies studied experienced breakthrough seizures, with most occurring in the first trimester.

This is a practical problem because falling lamotrigine levels mean less seizure protection at a time when seizure control matters enormously, both for the mother’s safety and for the pregnancy. The standard approach is to monitor blood levels regularly and increase the dose as needed. Some clinicians advocate for preemptive dose adjustments rather than waiting for breakthrough seizures or lab results to trigger changes.¹⁶ This is an area where close collaboration between neurologist and obstetrician pays off.

The drug also crosses the placenta rapidly, reaching detectable levels in fetal circulation within about 15 minutes in perfusion studies. At birth, cord blood concentrations are roughly equivalent to maternal blood levels, and in some cases slightly higher.¹⁷ This full placental transfer is worth knowing about, though it has not been linked to specific adverse neonatal outcomes beyond what is captured in the malformation and neurodevelopmental data.

The Postpartum Rebound

If pregnancy drives lamotrigine levels down, delivery does the opposite, and it happens fast. After birth, as estrogen levels plummet, the enzyme that was clearing lamotrigine so efficiently slows down. The drug starts accumulating again. In one study of women with bipolar disorder taking lamotrigine, serum levels increased an average of 154% compared with third-trimester levels within five weeks of delivery. The most dramatic jump happened about a week and a half after giving birth, and in some women the increase was as high as 640% above the first level obtained during pregnancy.¹⁸

This matters because excessively high lamotrigine levels cause toxicity symptoms: dizziness, double vision, nausea, coordination problems. If the dose was raised during pregnancy to compensate for increased clearance, it needs to be tapered back down after delivery. An empiric postpartum taper has been shown to reduce the likelihood of maternal toxicity.¹⁶ The timing and pace of that taper vary by individual, which is another reason ongoing blood level monitoring matters during the weeks after delivery.

Neurodevelopmental Outcomes in Exposed Children

Birth defects visible at delivery are only one piece of the safety picture. Parents also want to know whether prenatal lamotrigine exposure affects how children develop cognitively over time. The data here are mostly reassuring, with one caveat about the youngest age group.

A systematic review and meta-analysis looking at neurodevelopmental outcomes found a statistically significant increase in cognitive developmental delay in infants under three years old who had been exposed to lamotrigine in utero. However, the number of exposed children in those studies was small (42 exposed versus 86 unexposed). In older children aged three to six, the increase was not statistically significant, and in children older than six, there was no increased risk at all. Studies that specifically looked for severe cognitive delay found no significant increase in any age group.¹⁹

The autism question has also been studied directly. A large Nordic study tracking thousands of children born to mothers with epilepsy found that lamotrigine exposure carried no increased risk of autism, with an adjusted hazard ratio of 1.00 compared to unexposed children. Valproate, by contrast, was associated with a roughly 2.7-fold increase in autism incidence.²⁰ For parents weighing the long-term developmental implications, this is among the most reassuring findings in the lamotrigine safety literature.

Miscarriage, Preterm Birth, and Other Obstetric Outcomes

Beyond birth defects and neurodevelopment, a systematic review and meta-analysis examined whether lamotrigine exposure increased the risk of other adverse pregnancy outcomes. Rates of miscarriage, stillbirth, preterm delivery, and small-for-gestational-age neonates were not found to be increased after in-utero lamotrigine exposure compared with the general population.²¹ This is a separate and important dimension of safety. Some medications that do not cause structural birth defects can still increase the risk of pregnancy complications, but lamotrigine does not appear to do that.

Breastfeeding While Taking Lamotrigine

Because lamotrigine crosses the placenta freely, new mothers reasonably wonder whether it passes into breast milk and poses risks to nursing infants. It does appear in breast milk, and infant serum levels can be measurable. But in a study that followed 20 mother-infant pairs through the first month after delivery, none of the infants developed serious adverse events. Some minor findings like skin rash, jaundice, and drowsiness were observed, but these occurred at rates that were not significantly different from a control group of mothers not taking lamotrigine.²² The evidence base for breastfeeding safety is smaller than for pregnancy outcomes, but the available data suggest that low to moderate doses are compatible with breastfeeding, at least in the early postpartum period.

Folic Acid Supplementation

Folic acid supplementation is standard advice for all pregnant women, but it takes on extra importance for women on antiseizure medications. Some of these drugs interfere with folate metabolism, and folate deficiency is a known contributor to neural tube defects. For women taking lamotrigine, periconceptional folic acid use has been associated with lower risk of adverse neurodevelopmental outcomes and preterm birth in children exposed to antiseizure medications prenatally, though the evidence that it specifically reduces the risk of congenital malformations remains uncertain.²³

Most guidelines recommend starting folic acid before conception, ideally at least one to three months before becoming pregnant. The recommended dose for women on antiseizure medications is typically higher than the standard prenatal dose, though the exact amount varies by guideline and by which medication is being taken. If you are on lamotrigine and considering pregnancy, starting folic acid early is one of the simplest protective steps you can take, even though the specific mechanism of its benefit alongside lamotrigine is still being worked out.

What About Women Taking Lamotrigine for Bipolar Disorder?

Most of the pregnancy registry data come from women with epilepsy, since that is the condition for which lamotrigine was originally approved and most heavily tracked. But lamotrigine is widely prescribed as a mood stabilizer for bipolar disorder, and women taking it for mood stability face many of the same questions. The pharmacokinetic changes during pregnancy, including the drop in blood levels and the postpartum rebound, apply regardless of the underlying diagnosis. A study specifically tracking women with bipolar disorder on lamotrigine documented the same dramatic swings in drug levels, with postpartum levels rising an average of 402% above the baseline during pregnancy.¹⁸

The clinical challenge for women with bipolar disorder is somewhat different from epilepsy. Subtherapeutic lamotrigine levels during pregnancy could trigger depressive episodes rather than seizures, and postpartum mood instability is already a heightened risk period for women with bipolar disorder. Losing medication efficacy at exactly the wrong time compounds that vulnerability. Close monitoring and proactive dose management are just as important for psychiatric use as they are for seizure control, but the coordination may involve a psychiatrist rather than (or in addition to) a neurologist.

The malformation data are generally applied across indications since the drug is the same molecule at similar doses. There is no evidence that the birth defect risk profile differs based on the reason you are taking lamotrigine. What can differ is the clinical stakes of losing seizure or mood control during pregnancy, which affects how aggressively dose adjustments should be pursued.